185 related articles for article (PubMed ID: 32986380)
1. Circulation EBV Mir-Bart-7 Relating to Clinical Manifestation in Nasopharyngeal Carcinoma.
Wardana T; Gunawan L; Herawati C; Oktriani R; Anwar S; Astuti I; Aryandono T; Mubarika S
Asian Pac J Cancer Prev; 2020 Sep; 21(9):2777-2782. PubMed ID: 32986380
[TBL] [Abstract][Full Text] [Related]
2. Circulating Epstein-Barr virus microRNAs miR-BART7 and miR-BART13 as biomarkers for nasopharyngeal carcinoma diagnosis and treatment.
Zhang G; Zong J; Lin S; Verhoeven RJ; Tong S; Chen Y; Ji M; Cheng W; Tsao SW; Lung M; Pan J; Chen H
Int J Cancer; 2015 Mar; 136(5):E301-12. PubMed ID: 25213622
[TBL] [Abstract][Full Text] [Related]
3. Circulating Epstein-Barr virus microRNAs BART7-3p and BART13-3p as novel biomarkers in nasopharyngeal carcinoma.
Lu T; Guo Q; Lin K; Chen H; Chen Y; Xu Y; Lin C; Su Y; Chen Y; Chen M; Zheng Y; Ye Y; Lin S; Zong J; Pan J
Cancer Sci; 2020 May; 111(5):1711-1723. PubMed ID: 32155300
[TBL] [Abstract][Full Text] [Related]
4. EBV-encoded miRNAs target ATM-mediated response in nasopharyngeal carcinoma.
Lung RW; Hau PM; Yu KH; Yip KY; Tong JH; Chak WP; Chan AW; Lam KH; Lo AK; Tin EK; Chau SL; Pang JC; Kwan JS; Busson P; Young LS; Yap LF; Tsao SW; To KF; Lo KW
J Pathol; 2018 Apr; 244(4):394-407. PubMed ID: 29230817
[TBL] [Abstract][Full Text] [Related]
5. Vesicle-bound EBV-BART13-3p miRNA in circulation distinguishes nasopharyngeal from other head and neck cancer and asymptomatic EBV-infections.
Ramayanti O; Verkuijlen SAWM; Novianti P; Scheepbouwer C; Misovic B; Koppers-Lalic D; van Weering J; Beckers L; Adham M; Martorelli D; Middeldorp JM; Pegtel DM
Int J Cancer; 2019 May; 144(10):2555-2566. PubMed ID: 30411781
[TBL] [Abstract][Full Text] [Related]
6. Epstein-Barr virus encoded microRNA BART7 regulates radiation sensitivity of nasopharyngeal carcinoma.
Gao W; Li ZH; Chen S; Chan JY; Yin M; Zhang MJ; Wong TS
Oncotarget; 2017 Mar; 8(12):20297-20308. PubMed ID: 28423621
[TBL] [Abstract][Full Text] [Related]
7. EBV-miR-BART7-3p promotes the EMT and metastasis of nasopharyngeal carcinoma cells by suppressing the tumor suppressor PTEN.
Cai LM; Lyu XM; Luo WR; Cui XF; Ye YF; Yuan CC; Peng QX; Wu DH; Liu TF; Wang E; Marincola FM; Yao KT; Fang WY; Cai HB; Li X
Oncogene; 2015 Apr; 34(17):2156-66. PubMed ID: 25347742
[TBL] [Abstract][Full Text] [Related]
8. Gold nano-particles (AuNPs) carrying anti-EBV-miR-BART7-3p inhibit growth of EBV-positive nasopharyngeal carcinoma.
Cai L; Li J; Zhang X; Lu Y; Wang J; Lyu X; Chen Y; Liu J; Cai H; Wang Y; Li X
Oncotarget; 2015 Apr; 6(10):7838-50. PubMed ID: 25691053
[TBL] [Abstract][Full Text] [Related]
9. Systematic comparison of plasma EBV DNA, anti-EBV antibodies and miRNA levels for early detection and prognosis of nasopharyngeal carcinoma.
Tan LP; Tan GW; Sivanesan VM; Goh SL; Ng XJ; Lim CS; Kim WR; Mohidin TBBM; Mohd Dali NS; Ong SH; Wong CY; Sawali H; Yap YY; Hassan F; Pua KC; Koay CE; Ng CC; Khoo AS;
Int J Cancer; 2020 Apr; 146(8):2336-2347. PubMed ID: 31469434
[TBL] [Abstract][Full Text] [Related]
10. Detection of Epstein-Barr virus (EBV)-encoded microRNAs in plasma of patients with nasopharyngeal carcinoma.
Gao W; Wong TS; Lv KX; Zhang MJ; Tsang RK; Chan JY
Head Neck; 2019 Mar; 41(3):780-792. PubMed ID: 30548946
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of Epstein-Barr virus-encoded microRNA-BART7 in undifferentiated nasopharyngeal carcinoma.
Chan JY; Gao W; Ho WK; Wei WI; Wong TS
Anticancer Res; 2012 Aug; 32(8):3201-10. PubMed ID: 22843893
[TBL] [Abstract][Full Text] [Related]
12. Epstein-Barr virus mir-bart1-5p detection via nasopharyngeal brush sampling is effective for diagnosing nasopharyngeal carcinoma.
Zheng XH; Lu LX; Cui C; Chen MY; Li XZ; Jia WH
Oncotarget; 2016 Jan; 7(4):4972-80. PubMed ID: 26701721
[TBL] [Abstract][Full Text] [Related]
13. NF-κB Signaling Regulates Expression of Epstein-Barr Virus BART MicroRNAs and Long Noncoding RNAs in Nasopharyngeal Carcinoma.
Verhoeven RJ; Tong S; Zhang G; Zong J; Chen Y; Jin DY; Chen MR; Pan J; Chen H
J Virol; 2016 Jul; 90(14):6475-88. PubMed ID: 27147748
[TBL] [Abstract][Full Text] [Related]
14. Epstein-Barr Virus MicroRNA miR-BART5-3p Inhibits p53 Expression.
Zheng X; Wang J; Wei L; Peng Q; Gao Y; Fu Y; Lu Y; Qin Z; Zhang X; Lu J; Ou C; Li Z; Zhang X; Liu P; Xiong W; Li G; Yan Q; Ma J
J Virol; 2018 Dec; 92(23):. PubMed ID: 30209170
[TBL] [Abstract][Full Text] [Related]
15. Profiling of Epstein-Barr virus-encoded microRNAs in nasopharyngeal carcinoma reveals potential biomarkers and oncomirs.
Wong AM; Kong KL; Tsang JW; Kwong DL; Guan XY
Cancer; 2012 Feb; 118(3):698-710. PubMed ID: 21720996
[TBL] [Abstract][Full Text] [Related]
16. EBV-miR-BART8-3p induces epithelial-mesenchymal transition and promotes metastasis of nasopharyngeal carcinoma cells through activating NF-κB and Erk1/2 pathways.
Lin C; Zong J; Lin W; Wang M; Xu Y; Zhou R; Lin S; Guo Q; Chen H; Ye Y; Zhang B; Pan J
J Exp Clin Cancer Res; 2018 Nov; 37(1):283. PubMed ID: 30477559
[TBL] [Abstract][Full Text] [Related]
17. Epstein-Barr virus-encoded microRNA BART22 serves as novel biomarkers and drives malignant transformation of nasopharyngeal carcinoma.
Zhang T; Chen Z; Deng J; Xu K; Che D; Lin J; Jiang P; Gu X; Xu B
Cell Death Dis; 2022 Jul; 13(7):664. PubMed ID: 35907914
[TBL] [Abstract][Full Text] [Related]
18. Circulating Epstein-Barr virus microRNA profile reveals novel biomarker for nasopharyngeal carcinoma diagnosis.
Wu L; Wang J; Zhu D; Zhang S; Zhou X; Zhu W; Zhu J; He X
Cancer Biomark; 2020; 27(3):365-375. PubMed ID: 31958073
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Epstein-Barr Virus Serological Tools for the Screening and Risk Assessment of Nasopharyngeal Carcinoma: a Large Population-based Study.
Guo J; Cui Z; Zheng Y; Li X; Chen Y
Pathol Oncol Res; 2020 Oct; 26(4):2185-2190. PubMed ID: 32222897
[TBL] [Abstract][Full Text] [Related]
20. Epstein-Barr virus-coded miR-BART13 promotes nasopharyngeal carcinoma cell growth and metastasis via targeting of the NKIRAS2/NF-κB pathway.
Xu YJ; Zhou R; Zong JF; Lin WS; Tong S; Guo QJ; Lin C; Lin SJ; Chen YX; Chen MR; Chen HL; Ye YB; Pan JJ
Cancer Lett; 2019 Apr; 447():33-40. PubMed ID: 30684592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
